← Eichor
Study identifier: NCT03852407 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning

Condition: Acute Myeloid Leukemia in Remission · Myelodysplastic Syndromes · Chronic Myeloid Leukemia in Remission  ·  Sponsor: University of Liege

PhasePhase 2
Planned participants114
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

The present project aims at comparing two conditioning regimens (FM-PTCy vs FM-ATG). The hypothesis is that one or the two regimens will lead to a 2-year cGRFS rate improvement from 30% (the cGRFS rate with FM without ATG/PTCy) to 45% (Pick-a-winner phase 2 randomized study).

This description comes directly from the study's public registry record.

Talk to the study team

Frédéric Baron, MD,Ph  ·  +32 4 366 72 01  ·  F.Baron@uliege.be

Always discuss trial participation with your own doctor first.

Locations (10)

ZNA StuivenbergAntwerp, BelgiumRecruiting
AZ Sint Jan BruggeBruges, BelgiumRecruiting
IJ BordetBrussels, BelgiumRecruiting
UZ BrusselBrussels, BelgiumRecruiting
UCL St LucBrussels, BelgiumRecruiting
UZ GentGhent, BelgiumRecruiting
UZ LeuvenLeuven, BelgiumRecruiting
CHU de LiègeLiège, BelgiumRecruiting
AZ Delta RoeselareRoeselare, BelgiumRecruiting
CHU UCL Namur GodinneYvoir, BelgiumRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03852407